Cipla Ltd · NSE:CIPLA

Cipla — Q2 FY2022 Earnings Presentation

14 slides from Cipla's earnings presentation, Oct 26, 2021

  1. Slide 1: Investor Presentation Q2FY22

    CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q2FY22 October 26, 2021

  2. Slide 2: Disclaimer

    DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o

  3. Slide 3: Strong traction in core therapies drives Q2FY22 performance

    Strong traction in core therapies across branded markets and CLICK respiratory continued TO EDIT MASTER TITLE STYLE momentum in the US drive Q2FY22 performance Overall Revenue Overall EBITDA Strong delivery across 10% branded & generic markets; 4% EBITDA Margin Covid contribution (Q2 YoY Growth in I

  4. Slide 4: Strong capital structure and robust free cash flow generation continues

    Strong capital structure and robust free cash flow CLICK TO generation EDIT MASTER continues TITLE STYLE in Q2FY22 Net Cash / Equity Cash Balances2 (INR Cr) 0.12 3,676 3,557 0.10 Mar'21 Sept'21 Mar'21 Sept'21 ▪ Growth in operating profitability and prudent working capital management drives robust fr

  5. Slide 5: Continued expansion in portfolio offerings with long-term partnerships

    Continued expansion in portfolio offerings with long-term CLICK TO&EDIT partnerships MASTERacross launches TITLE STYLE our strategic markets ✓ Strategic partnership with Eli Lily for diabetic products Humalog® One India and TrulicityTM ✓ New launches in CNS, Respiratory and ARV therapies to South Af

  6. Slide 6: Financial Performance – Q2FY22

    Financial Performance – Q2FY22 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,520 Cr 10% YoY EBITDA INR 1,226 Cr │ 22.2% 4% YoY Q2 FY22 (Consolidated) Revenue1 Break-up Actuals API, 3% Others, 1% vs Q2 FY 21 (Rs Cr) International Total Revenue from Markets, 5,520 10% Operations 15% EBITDA 1,226 4%

  7. Slide 7: One India: Consistent execution driving growth across businesses in India

    One India (Rx + Gx+ CHL1): Consistent execution driving CLICK growth TO EDIT across MASTER TITLE businesses STYLE in India Key Business Highlights One India Branded prescription business ❖ Sustained volume traction across therapies in core portfolio Rs. Cr Q2 Y-o-Y ❖ Acute and respiratory nebulizati

  8. Slide 8: Global consumer health franchise gaining traction

    Global consumer health franchise gaining traction CLICK TO EDIT MASTER TITLE STYLE 7.0+% contribution to overall revenues in H1FY22; Improving consumer health outcomes Anchor consumer brands in India1 Anchor consumer brands in South Africa 13% #1 #1 41% Pain Relief Category (H1FY22 NRT* (H1FY22 YoY

  9. Slide 9: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access

    SAGA1: South Africa, Sub-Saharan Africa and Cipla Global CLICK TO EDIT MASTER TITLE STYLE Access Key Business Highlights SAGA: 8% Y-o-Y South Africa $ Mn ❖ Continued market beating growth in South Africa SA Private (SA) private business; tender business performed in- market Q2 Y-o-Y line with expect

  10. Slide 10: North America: Continued traction in core formulation portfolio

    North America: Continued traction in core formulation CLICK TO EDIT MASTER TITLE STYLE portfolio Key Business Highlights North America US Generics ramp-up to multi-quarter high ❖ Steady momentum in core products offsetting price erosion in rest of the $ Mn portfolio Q2 Y-o-Y ❖ New approval: Diflupre

  11. Slide 11: ANDA & NDA Portfolio & Pipeline (As on 30th September)

    ANDA & NDA1 Portfolio & Pipeline (As on 30th September CLICK TO EDIT MASTER TITLE STYLE 2021) Total ANDAs 166 18 72 256 & NDAs 18 59 8 4 20 81 8 3 1 9 40 5 Approved Tentatively Under Approval ANDAs/NDAs Approved ANDAs ANDAs/NDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs 1 Does not include Vet produ

  12. Slide 12: International Markets and API

    International Markets and API CLICK TO EDIT MASTER TITLE STYLE International Markets API $ Mn $ Mn Q2 Y-o-Y Q2 Y-o-Y 120 14% 111 97 100 80 60 25 -9% 23 40 20 - Q2FY21 Q2FY22 Q2FY21 Q2FY22 Key Business Highlights Key Business Highlights ❖ Emerging markets business resumed middle eastern supplies, dem

  13. Slide 13: Our FY22 priorities include

    Our FY22 priorities include CLICK TO EDIT MASTER TITLE STYLE Maintain growth momentum in large branded and unbranded generic franchises of India, South Africa and augment consumer wellness franchise Ensuring Covid portfolio availability and maximize patient reach Expanding lung leadership globally a

  14. Slide 14: Thank You

    Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com

Cipla — Q2 FY2022 Earnings Presentation on 6ix